Kinfo
Candel Therapeutics, Inc. logo

Candel Therapeutics, Inc.

CADLNASDAQHealthcare·US · USD
$5.40
-0.41 (-7.06%)
Prices as of November 17, 2026 · market closed

Price

Key statistics

Valuation
Market cap423.61M USD
Enterprise value333.02M USD
Trailing P/E-7.51
Forward P/E-4.10
PEG ratio-0.02
Price / sales0.00
Price / book3.51
Profitability
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on assets-33.54%
Return on equity-93.65%
Income (TTM)
Revenue0.00 USD
Gross profit0.00 USD
EBITDA-81.10M USD
Net income-99.14M USD
Diluted EPS-$1.53
Rev. growth (YoY)0.00%
Balance sheet
Total cash203.12M USD
Total debt49.77M USD
Debt / equity37.82
Current ratio7.57
Book value / share$1.68
Cash flow (TTM)
Operating cash flow-68.91M USD
Levered free cash flow-26.53M USD
Shares & price
Shares outstanding76.12M
Float62.15M
Held by institutions67.17%
Beta-0.29
50-day MA$9.75
200-day MA$8.40
52-week high$14.00
52-week low$4.35
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-11-12-0.31-0.27+12.90%2026-08-13-0.23-0.36−56.52%2026-05-14-0.33-0.14+57.58%2026-05-040.780.87+11.54%2026-03-12-0.23-0.29−26.09%
About Candel Therapeutics, Inc.

Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing viral immunotherapies for cancer. Candel Therapeutics concentrates on off-the-shelf, multimodal biological therapies designed to stimulate anti-tumor immune responses and address solid tumors. Its current pipeline includes CAN-2409, an adenovirus-based program being evaluated in cancers such as prostate, non-small cell lung, and pancreatic cancer, as well as CAN-3110, a herpes simplex virus-based candidate for recurrent high-grade glioma. The company also develops the enLIGHTEN Discovery Platform, which is used to identify and advance new viral immunotherapy candidates. Headquartered in Needham, Massachusetts, Candel Therapeutics plays a specialized role in oncology by combining viral engineering with immunology to support the development of targeted cancer treatments.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Paul-Peter Tak FOCIS, M.D., Ph.D.
Employees
55
Headquarters
Needham, MA, United States

Frequently asked questions about Candel Therapeutics, Inc.